The JAK2V617F Point Mutation Increases the Osteoclast Forming Ability of Monocytes in Patients with Chronic Myeloproliferative Neoplasms and Makes their Osteoclasts more Susceptible to JAK2 Inhibition
Received: July 3, 2018
Accepted: September 16, 2018
Mediterr J Hematol Infect Dis 2018, 10(1): e2018058 DOI 10.4084/MJHID.2018.058
| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
is a gain of function point mutation that occurs in Myeloproliferative
Neoplasm (MPN) patients and deranges their hemopoiesis at cellular
level. We speculate that hyperfunctioning JAK2 can modify osteoclast
(OCL) homeostasis in MPN patients. We studied
JAK2 is an intracellular kinase, a cellular hub, that acts as a second mediator of intracellular signaling from a variety of cytokine and hormone receptors.[7,8] Pharmacological inhibition of the JAK2 kinase reduces osteoclast bone resorting activity,[9-12] suggesting that the intact JAK2 function is essential for normal osteoclast function.
The JAK2V617F is a gain of function point mutation that often occurs in patients with myeloproliferative neoplasms (MPN) and deranges basic cellular functions of their hemopoietic cells.[13,14] JAK2V617F arises in an early myeloid progenitor cell, cells ancestor to OCLs. Except intrinsic stem cell defects, HSC niche deregulation in JAK2V617F mutated mice models of MPN contributes equally to MPN disease evolution.[1,15]
Therefore we speculate that genetically modified JAK2, as it occurs in MPN patients, can slightly modify osteoclast homeostasis in a way that deregulates hematopoietic stem cell niche homeostasis.
Patient’s Samples and Materials
JAK2V617F mutation detection in our patient’s cohort. Genomic DNA was extracted from whole blood (QIAGEN), and 25 ng of gDNA were subjected to Allele-specific PCR (ASO-PCR) for the detection of the JAK2V617F mutation according to the protocol described by Baxter et al., slightly modified. Restriction Length Polymorphism method (RFLP) by using the BsaXI restriction enzyme, was performed in all positive for the JAK2V617F mutation samples, to determine its presence in heterozygous or homozygous status.
Osteoclast (OCL) forming assays from monocyte cells derived from MPN patients. 2x105 positively selected monocyte cells, after checked for purity by flow cytometry, were suspended in a MEM medium + 10% Fetal Calf Serum, supplemented with optimum concentrations of osteclastogenic cytokines (RANKL 25 ng/ml and M-CSF 50 ng/ml) and then they were plated in a 48-flat bottom well plate. The half medium exchange was performed twice weekly, and the number of formed OCLs was scored under inverted microscope by using TRAP assays (Sigma Diagnostics) after staying 14 days in culture.
Quantitative Real-Time PCR (RT-PCR) for JAK2V617F/JAK2WT genomic DNA ratio measurement. Genomic DNA was extracted (QIAGEN) from both the input for OCL forming assays monocyte cells as well as from the OCLs that they were finally formed from them. JAK2V617F/JAK2WT genomic DNA ratio was calculated by using the Taqman based JAK2MutaQuant Kit (IPSOGEN). Briefly, a pair of FAM-tracked hybridisation probes was used in two different reaction tubes, one of them specific for the G1849T JAK2 mutation and the other specific for the wild type sequence, together with a JAK2gDNA specific pair of primers. Appropriate serial dilutions of known numbers of mutated and wild type JAK2 transcripts were used in order to set the calibration plot. All assays were performed on an ABI Prism7500 analyser (Applied- Biosystems).
OCL forming assays in the presence of the JAK2 inhibitorAG-490(Tyrphostin). Initially, titration of the inhibitory dose of AG-490 on OCL formation assays was performed. Selected monocytes from three normal donors started OCL forming assays in the presence of serial dilutions of AG-490 dissolved in DMSO; range 0.01-100 μM. The 50% Inhibitory concentration (IC50) was determined at 20μM (Figure 2A). Then OCL forming assays were started from MPN patient’s monocytes as previously described, and concurrently OCL forming assays in the presence of 2μM and 20μM of the JAK2 inhibitor AG-490 (Tyrphostin) dissolved in DMSO were also started.
CTXβ in serum measurement by ELISA and Colony Forming Assays from CD34 selected cells from the peripheral blood. CTXβ levels in whole blood serum were measured by ELISA (β- crossLaps/serum kit, Roche Diagnostics). Data are expressed as ng/ml.
Statistical analysis. All values represent median values (min-max). Comparisons between groups were performed by using the Mann-Whitney for unpaired and the Wilconxon Rank test for paired samples. Statistical significance was considered at the level of p<0.05 value. The SPSS-13 statistical package was used for statistical analysis.
The presence of the JAK2V617F point mutation enhances in-vitro OCL forming ability. OCLs were formed from monocyte cells derived from ND, and JAK2 mutated or unmutated MPN patients (an example is given in Figure 1A). OCLs derived from heterozygous for the JAK2V617F mutation (Het) MPN patients, were significantly more compared to those from the JAK2 wild type (WT) MPN patients and ND as well; Median OCLs per 10.000 monocytes, (min- max): JAK2V617F (Het) MPN: 960 (159-3674), JAK2 WT MPN: 204 (81-1286) and p=0.03 Mann-Whitney test (Figure 1B). Considering ND the Median (min-max) OCLs per 10.000 monocytes were: 322 (215-522) and p=0.05 when compared to JAK2V617F (Het) MPN patients (Figure 1B).
OCLs derived from JAK2V617F(Het) monocytes are enriched for the mutated clone compared to the input monocyte cells reflecting an increased outgrowth of the JAK2 V617F mutated clone. We then performed quantitative Taqman based RT-PCR assays at genomic DNA level, in both the input monocyte cells and in the OCLs that were finally derived from them, aiming to clarify whether the increased OCL formation noted from JAK2V617F (Het) MPN monocytes reflects outgrowth of the wild type or the mutated clone. In all out of seven JAK2V617F (Het) MPN patients successfully tested, the ratio of JAK2V617F/JAK2WT genomic DNA was increased in the OCLs fraction compared to the input monocyte cells. The median enrichment of OCLs for the JAK2V617F mutated clone was 12% (range: 3.3%-26%) and p<0.01, Wilconxon Rank test (Figure 1C).
No evidence by CTXβ of increased OCL activity in JAK2 V617F patients. The ability of JAK2 (Het) for higher OCL formation ex vivo poses the question if these patients have in higher levels of osteoclast activity in vivo. Therefore we quantified in serum from our MPN patients the levels of CTXβ by ELISA but we cannot find any difference among groups [median Value (min- max) JAK2 (Het): 1,013(0,9-2,1 ng/ml) JAK2 WT: 1,014(0,78-2,1 ng/ml, p=0,69 Data not shown).
In Vitro Osteoclastogenesis from monocyte cells derived from MPN patients is dependent upon JAK2 function. In order to address the dependence of osteoclastogenesis from JAK2 kinase in mutated and unmutated cells we performed OCL forming assays under titrated inhibition of the JAK2 kinase by the selective JAK2 inhibitor AG-
490. We determined IC50 in OCL forming assays performed from 3 ND monocytes at 20μΜ (Figure 2A). Afterwards, we performed OCL inhibition assays under titrated concentrations of AG490 at 2μΜ and 20μΜ in MPN patients. OCL inhibition is dose dependent in both groups of MPN patients (Table 1) but it has a significantly suppressing effect on OCL formation only in JAK2 (Het) MPN patients compared to ND. Of Note, at the higher inhibitory concentration of 20 μΜ OCL formation in samples from JAK2V617F (Het) patients was significantly reduced compared to ND (Table 1, p=0,02) and compared to JAK2 WT MPN patients as well (p=0,05). There was no statistically significant difference between ND and JAK2 WT MPN (p=0,28, Figure 2B).
|Table 1. Median OCL formed under titrated inhibition with the JAK2 inhibitor AG490.|
We then tried to address if this ex vivo effect of JAK2V617F on OCL formation has a detectable in vivo effect. Therefore we assessed osteoclastogenic activity in the serum of our patients by measuring CTXβ levels finding no difference between both groups. These data suggest that the in vivo effect of JAK2V617F on OCL formation and finally on the bones is not so robust in order to be detected by CTXβ levels.
In order to provide further insight to the dependence of MPN osteoclastogenesis from the JAK2 kinase function, we performed OCL forming assays under titrated pharmacological inhibition of the JAK2 kinase with the selective JAK2 inhibitor AG-490 (Tyrphostin). We noted that osteoclastogenesis from cells carrying the JAK2V617F point mutation is more susceptible to JAK2 kinase inhibition than osteoclastogenesis from cells that are carrying the wild type JAK2 kinase in a dose dependent manner. Our data provide evidence for a therapeutic effect of JAK2 inhibitors in MPN patients through reversion of OCL deregulation.
Our data enforce a model of deregulated osteoclastogenesis in a disease characterised by the genetically modified JAK2 kinase. In this study, we found out that the acquisition of the JAK2V617F point mutation in hematopoietic cells capable of osteoclastogenesis increases their OCL forming ability, but these OCLs are also more vulnerable to JAK2 kinase inhibition. This poses to us the challenge to extrapolate the underlying mechanism of increased osteoclastogenesis in JAK2V617F mutated cells and furthermore to perform OCL functional assays in a cohort of MPN patients enriched in patients homozygous for the JAK2 mutation. Targeting osteoclasts may be of value in MPN patients.
- Sanchez-Aguilera A, Mendez-Fer S. The hematopoietic stem-cell niche in health and leukemia Cell. Mol. Life Sci. 2017, 74:579–590. https://doi.org/10.1007/s00018-016-2306-y PMid:27436341 PMCid:PMC5272896
A, Abou-Ezzi G, Sitnicka E, W Jacobsen SE, Wakkach A, Blin-Wakkach C.
Osteoclasts promote the formation of hematopoietic stem cell niches in
the bone marrow. J Exp Med. 2012 Mar 12;209(3):537-49. https://doi.org/10.1084/jem.20110994 PMid:22351931 PMCid:PMC3302238
S, Ersek A, Ferraro F, Dazzi F, Horwood NJ. Inhibition of osteoclast
function reduces hematopoietic stem cell numbers in vivo. Blood. 2011
Feb 3;117(5):1540-9. https://doi.org/10.1182/blood- 2010-05-282855 PMid:21131587
K, Yoshida S, Kawasumi M, Hashimoto K, Kimura T, Sato Y, Kobayashi T,
Miyauchi Y, Hoshi H, Iwasaki R, Miyamoto H, Hao W, Morioka H, Chiba K,
Kobayashi T, Yasuda H, Penninger JM, Toyama Y, Suda T, Miyamoto T.
Osteoclasts are dispensable for hematopoietic stemcell maintenance and
mobilization. J Exp Med. 2011 Oct 24; 208(11):2175-81. https://doi.org/10.1084/jem.20101890 PMid:22006978 PMCid:PMC3201203
O, Dar A, Shivtiel S, Kalinkovich A, Lapid K, Sztainberg Y, Tesio M,
Samstein RM, Goichberg P, Spiegel A, Elson A, Lapidot T. Osteoclasts
degrade endosteal components and promote mobilization of hematopoietic
progenitor cells. Nat Med. 2006 Jun;12(6):657-64. https://doi.org/10.1038/nm1417 PMid:16715089
C, Moscatelli I, Thudium CS, Gudmann NS, Thomsen JS, Bruel A, Karsdal
MA, Henriksen K, Richter J. Osteoclasts are not crucial for
hematopoietic stem cell maintenance in adult mice. Haematologica 2013,
98(12):1848–1855. https://doi.org/10.3324/haematol.2013.089466 PMid:24097632 PMCid:PMC3856959
- Rawlings JS, Rosler KM, Harrison DA, The JAK/STAT signaling pathway. J Cell Sci. 2004; 117: 1281– 1283. https://doi.org/10.1242/jcs.00963 PMID: 15020666
- Murray PJ, The JAK-STAT signaling pathway: input and output integration. J Immunol. 2007; 178: 2623–2629. https://doi.org/10.4049/jimmunol.178.5.2623 PMid:17312100
HB, Kim HS, Lee MS, Kim KJ, Choi EY, Choi MK, Kim JJ, Cho HJ, Kim JW,
Bae JM, Kim YK, Park BH, Ha H, Chun CH, Oh J. Pyridone6, a
pan-Janus-activated kinase inhibitor, suppresses
osteoclast formation and bone resorption through down-regulation of receptor activator of nuclear factor-kappaB (NF-kappaB) ligand (RANKL)-induced c-Fos and nuclear factor of activated T cells (NFAT) c1 expression. Biol Pharm Bull. 2009 Jan;32(1):45-50. https://doi.org/10.1248/bpb.32.45 PMid:19122279
CH, Zhao JX, Sun L, Yao ZQ, Deng XL, Liu R, Liu XY. AG490 inhibits
NFATc1expression and STAT3 activation during RANKL induced
osteoclastogenesis. Biochem Biophys Res Commun 2013 Jun 14:
435(4):533-9. https://doi.org/10.1016/j.bbrc.2013.04.084 PMid:23665018
Park, Jennifer Lee, Mi-Ae Lim, Eun Kyung Kim, Sung Min Kim, JunGeolRyu,
Jae Ho Lee, Seung-Ki Kwok, kyung-Su Park, Ho- Youn Kim, Sung-Hwan Park,
Mi-La Cho. JAK2-STAT3 Blockade by AG490 Supresses autoimmune arthritis
in mice via reciprocal regulation of T cells and Th17 cells. Journal of
Immunology 2014; 192:4417-24. https://doi.org/10.4049/jimmunol.1300514 PMid:24688026
K, Kobayashi Y, Uehara S, Suzuki T, Koide M, Yamashita T, et al. A
Jak1/2 inhibitor, baricitinib, inhibits osteoclastogenesis by
suppressing RANKL expression in osteoblasts in vitro. PLoSONE 2017,
12(7): e0181126. https://doi.org/10.1371/journal. pone.0181126
AJ, Chowdhury O, Pecquet C, Dusa A, Woll P, Atkinson D, Burns A, Score
J, Rugless M, Clifford R, Moule S, Bienz N, Vyas P, Cross N, Gale RE,
Henderson S, Constantinescu SN, Schuh A, Jacobsen SE. Impact of
germline JAKV617F mutation in human hematopoiesis. Blood. 2013 May
16;121(20):4156-65. https://doi.org/10.1182/blood-2012-05-430926 PMid:23535062
F, Rumi E, Pietra D, Della Porta MG, Boveri E, Pascutto C, Vanelli L,
Arcaini L, Burcheri S, Malcovati L, Lazzarino M, Cazzola M. Relation
between JAK2 (V617F) mutation status, granulocyte activation, and
constitutive mobilization of CD34+ cells into peripheral blood in
myeloproliferative disorders. Blood. 2006 May 1;107(9):3676-82. https://doi.org/10.1182/blood-2005-09-3826 PMid:16373657
- Arranz L, Sanchez-Aguilera A, Martin-Perez D, Isern J, Langa X, Tzankov A, Lundberg P, Muntion S, Tzeng YS, Lai DM, Schwaller J, Skoda RC, Mendez-Ferrer S (2014) Neuropathy of haematopoietic stem cell niche is essential for myeloproliferative neoplasms. 512, Nature Aug 2014; 78–81. https://doi.org/10.1038/nature13383